ACR Convergence 2025 speakers reviewed new fibromyalgia insights, from the first new drug approval since 2009 to nociplastic pain concepts & cognitive behavioral therapy.
Emerging Treatments in Psoriatic Arthritis
At a scientific session of ACR Convergence 2025, Alexis Ogdie, MD, discussed new and forthcoming treatments for psoriatic arthritis.
Meet Incoming ARP President Rebecca Cleveland
Incoming ARP President Dr. Rebecca Cleveland discusses her plans for advocacy, ACR/ARP collaboration, & tackling workforce shortages in rheumatology.
Meet New ACR President William (Will) F. Harvey
Incoming ACR President Will Harvey shares his strategy for fighting reimbursement cuts, funding threats & workforce shortages through advocacy & member engagement.
Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.
Gout & Cardiometabolic Co-Morbidities
ACR 2025 experts explore gout’s deep ties to MetS, insulin resistance & cardiovascular mortality, weighing new data on colchicine, febuxostat & SGLT2 inhibitors.
What’s New in Psoriatic Arthritis?
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
Let’s Discuss: Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
Promising Combination Treatment for Gout
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.
FDA Approves 2 More Denosumab Biosimilars
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.
- 1
- 2
- 3
- …
- 835
- Next Page »